An in vitro experimental study and clinical applications of MR angiography with low-dose contrast agent of lower limb arteries at 3.0 T

Chinese Journal of Radiology

Volumn 44, Issue 10, 2010, Pages 1078-1083

  Zhang, Lei ^a   Chang, Jian ^a   Shi, Dong Chun ^a   Gu, Hong Bin ^a   Li, Ke ^a   Zhu, Lei ^a   Hu, Zi Jian ^a   Jin, Zhen ^a   Xu, Zhang Rong ^a  

^a 306 HOSPITAL OF PLA   (China)

Author keywords

Arterioles; Contrast media; Diabetic angiopathies; Lower extremity; Magnetic resonance angiography

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM PENTETATE;

ARTERY OCCLUSION; ARTICLE; CONCENTRATION (PARAMETERS); CONTRAST ENHANCEMENT; DIABETIC PATIENT; DIAGNOSTIC ACCURACY; DIGITAL SUBTRACTION ANGIOGRAPHY; EXPERIMENTAL STUDY; FEASIBILITY STUDY; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; IN VITRO STUDY; LEG ARTERY; MAGNETIC RESONANCE ANGIOGRAPHY; MAJOR CLINICAL STUDY; PELVIS ANGIOGRAPHY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; THIGH;

EID: 84860905611     PISSN: 10051201     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.1005-1201.2010.10.017     Document Type: Article

References (18)

1. Dellegrottaglie S, Sanz J, Macaluso F, et al. Technology Insight: magnetic resonance angiography for the evaluation of patients with peripheral artery disease. Nat Clin Pract Cardiovasc Med, 2007, 4: 677-687.
2. Tongdee R, Narra VR, McNeal G, et al. Hybrid peripheral 3D contrast-enhanced MR angiography of calf and foot vasculature. AJR, 2006, 186: 1746-1753.
3. 2004, 24: 314-316.
4. Grobner T. Gadolinium: a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Traasplant, 2006, 21: 1104-1108.
5. 2004, 12: 324-327.
6. 2005, 13: 412-415.
7. Mehran R, Nikolsky E. Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int Suppl, 2006: S11-S15.
8. Broome DR, Girguis MS, Baron PW, et al. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR, 2007, 188: 586-592.
9. Knopp MV, Lodemann M, Kage U, et al. Administration of MR contrast agents outside of approved indications (off-label use). Radiologe, 2001, 41: 296-302.
10. Mitsuzaki K, Yamashita Y, Onomichi M, et al. Delineation of simulated vascular stenosis with Gd-DTPA-enhanced 3D gradient echo MR angiography: an experimental study. J Comput Assist Tomogr, 2000, 24: 77-82.
11. Huegli RW, Aschwanden M, Bongartz G, et al. Intraarterial MR angiography and DSA in patients with peripheral arterial occlusive disease: prospective comparison. Radiology, 2006, 239: 901-908.
12. Kreitner KF, Kalden P, Neufang A, et al. Diabetes and peripheral arterial occlusive disease: prospective comparison of contrast-enhanced three-dimensional MR angiography with conventional digital subtraction angiography. AJR, 2000, 174: 171-179.
13. 2009, 17: 811-814.
14. Andreisek G, Pfammatter T, Goepfert K, et al. Peripheral arteries in diabetic patients: standard bolus-chase and time-resolved MR angiography. Radiology, 2007, 242: 610-620.
15. Lohan DG, Tomasian A, Saleh RS, et al. Ultra-low-dose, time-resolved contrast-enhanced magnetic resonance angiography of the carotid arteries at 3.0 tesla. Invest Radiol, 2009, 44: 207-217.
16. Bilecen D, Schulte AC, Heidecker HG, et al. Lower extremity: low-dose contrast agent intraarterial MR angiography in patients-initial results. Radiology, 2005, 234: 250-255.
17. Habibi R, Krishnam MS, Lohan DG, et al. High-spatial-resolution lower extremity MR angiography at 3.0 T: contrast agent dose comparison study. Radiology, 2008, 248: 680-692.
18. Ganguli S, Pedrosa I, Smith MP, et al. Low dose pedal magnetic resonance angiography at 3 tesla with time-resolved imaging of contrast kinetics: a feasibility study. Invest Radiol, 2008, 43: 650-655.